Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2016-01-26 Earnings Release
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
OLYSIO® sales during the fourth quarter 2015
Earnings Release Classification · 99% confidence The document is a short press release announcing specific financial results for the fourth quarter of 2015 related to OLYSIO® sales (44 MUSD) and royalty income (31 MSEK). It provides key figures and a comparison table. Crucially, it states that the full 'Financial Statement 2015' will be published later (February 18, 2016) and announces a subsequent conference call. Because this document only releases the key highlights of the period's performance and is not the comprehensive annual report (10-K) or the detailed interim report (IR), it fits the definition of an Earnings Release (ER). The document length is short (1840 chars), but its content is the actual release of results, not just an announcement of a future report release (which would be RPA/RNS). Q4 2015
2016-01-26 English
Försäljning för OLYSIO® under fjärde kvartalet 2015
Earnings Release Classification · 98% confidence The document is a short announcement from Medivir AB regarding the global net sales of OLYSIO® for the fourth quarter of 2015. It provides key financial figures (44 MUSD in sales, 31 MSEK in royalty) and a comparison table. Crucially, it states that the company 'kommer att publicera sin bokslutskommuniké för 2015 den 18 februari 2016' (will publish its year-end report for 2015 on February 18, 2016). Since this document only releases preliminary sales highlights for the period and announces the future release of the full report, it fits the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights only). It is too brief and focused on preliminary results to be a full Interim Report (IR) or Annual Report (10-K). Q4 2015
2016-01-26 Swedish
Medivir meddelar att Janssen avslutat utvecklingen av polymerashämmaren AL-704 för behandling av hepatit C
Legal Proceedings Report Classification · 99% confidence The document is a short announcement from Medivir AB regarding the termination of the development program for the drug candidate AL-704 by Janssen due to insufficient clinical antiviral effect in Hepatitis C patients. It details the status of the project, financial implications (no future royalties), and confirms that other projects are unaffected. The text concludes with contact information and a statement that the information is being made public according to securities market law, dated December 21, 2015. This type of announcement, detailing a specific corporate event (termination of a drug development collaboration/asset), is a general regulatory disclosure. Since it is not a formal financial report (10-K, IR, ER), a management discussion (MDA), or a specific transaction (CAP, TAR), it best fits the general regulatory announcement category, which is RNS (Regulatory Filings), as it is a material event disclosure that doesn't fit the other specific categories.
2015-12-21 Swedish
Medivir announces that development of the HCV nucleotide polymerase inhibitor AL-704 was terminated by Janssen
Regulatory Filings Classification · 95% confidence The document is a short press release announcing the termination of a drug development project (AL-704) by a partner (Janssen). It details the reason for termination (insufficient clinical antiviral activity) and the financial implications (no further revenues from that specific agreement). This type of announcement, which concerns a specific business event, partnership outcome, or material development that isn't a standard periodic financial report (like 10-K or IR) or a management change, fits best under the general 'Regulatory Filings' category (RNS) as a significant corporate event announcement, or potentially 'LTR' if viewed as a material business development/risk update, but RNS is the most appropriate general regulatory announcement fallback for non-standard news. Given the options, it is a specific corporate update that doesn't fit the other specialized codes (like DIV, CAP, MANG, ER). Therefore, RNS is the most suitable classification for this type of material, non-periodic announcement.
2015-12-21 English
Interim / Quarterly Report 2015
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Medivir AB covering the period January to September 2015. It contains detailed financial statements, including income statements, balance sheet summaries, and management commentary on business performance, research projects, and financial results. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2015
2015-11-20 Swedish
Interim / Quarterly Report 2015
Interim / Quarterly Report Classification · 100% confidence The document is titled 'MEDIVIR AB – INTERIM REPORT, THIRD QUARTER 2015'. It contains detailed financial statements, including net turnover, profit/loss, earnings per share, and cash flow for the third quarter and the first nine months of 2015. It also includes management commentary, CEO remarks, and a breakdown of operational expenses. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q3 2015
2015-11-20 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.